Where Scientific Discovery Takes Shape
Strategically located in leading innovation hubs, RMR’s life sciences portfolio spans specialized facilities that support breakthrough research and development. Across our life science and R&D environments, facilities are purpose-built to support high-intensity research while enabling teams to accelerate breakthrough therapies and emerging technologies.
Our track record
Our portfolio includes top-tier pharmaceutical, biotech and healthcare organizations driving breakthroughs in medicine and technology. These assets serve a critical role in advancing scientific progress, increasing speed to market and supporting industry partners whose work drives medical and technological transformation. RMR manages healthcare and life sciences real estate on behalf of its private and public capital partners, including Diversified Healthcare Trust (Nasdaq: DHC). To learn more about DHC, visit dhcreit.com.
Square Feet
Properties
life sciences assets under management*
As of February 23, 2026. *Total healthcare portfolio AUM: ~$6.3B
A sector backed by demographics & capital conviction
Life sciences real estate is supported by ongoing advances in healthcare, consistent investment in research and demographic trends that sustain long-term demand for care delivery and scientific capacity. As the sector matures, the facilities that enable this work are increasingly regarded as essential infrastructure.
Unprecedented Innovation
FDA novel drug approvals in 2025 were near the highest on record, while biotechnology activity has grown 22% over the past decade – driving demand for laboratory, R&D and specialized development space.
Demographic Tailwinds
Aging populations and rising life expectancy increase demand for healthcare services, medical technologies and drug development supporting sustained growth in research facilities.
Capital Momentum
Life sciences real estate is projected to grow at a 6.76% CAGR through 2034, reaching an estimated $6.76B market size. Institutional capital allocations continue to rise, with the sector now representing over 33% of alternative real estate portfolios.
Leasing & Employment Strength
Despite temporary market headwinds, leasing has stabilized, and U.S. life sciences employment reached record highs in late 2024, with further expansion expected.
Our approach
We prioritize serving tenants whose work depends on reliable, highly technically environments that cannot be easily replicated. Our strategy centers on specialized facilities, strong operator alignment and long-term relevance in markets anchoring the nation's research ecosystem.
Our assets are designed to support the operational intensity of laboratory, R&D and innovation tenants. From floor loading and ventilation standards to backup systems and compliance requirements, we prioritize infrastructure that enables scientific work to proceed without interruption. Our emphasis on building capability positions our properties as long-term homes for tenants advancing mission-critical research.
We focus on market with established ecosystems - including San Diego, Seattle and Raleigh - where proximity to universities, research institutions, talent pipelines and venture capital networks supports long-term tenant stability. These markets benefit from diversified demand across biotech, pharmaceutical development, medical technology and healthcare innovation, reducing reliance on any single subsector.
Life sciences organizations typically make significant capital investments in their space - equipment, lab buildouts, clean rooms, specialized ventilation and GMP infrastructure. These investments lead to longer lease terms, predictable occupancy behavior and collaborative planning around expansions and modernizations. RMR’s focus on supporting these needs helps strengthen tenant relationships and minimize turnover.
Leveraging RMR's construction and development capabilities, we invest thoughtfully in building systems, lab upgrades, mechanical enhancements and sustainability features. We prioritize capital projects that enhance reliability, support compliance and extend asset longevity in a sector where technical performance is non-optional.
Why RMR Life Sciences
We manage life sciences assets with an integrated model that unites asset management, engineering and property teams. The result is consistent uptime, rapid response and coordinated planning for high‑acuity spaces; so, research, clinical workflows and GMP operations proceed without disruption.
Vertically Integrated CRE Platform
RMR’s asset managers develop strategic plans for each property, informed by 40 years of CRE experience and our multidisciplinary platform to execute leasing, redevelopment and repositioning strategies.
Strategic Locations in Innovation Hubs
Our research assets are located in premier life sciences markets – including Boston/Cambridge, San Francisco and San Diego – offering proximity to academic institutions, talent pipelines, and venture capital networks.
Operational Efficiency & Sustainability
We integrate smart building technologies, high-performance systems and compliance-driven infrastructure to meet the specialized needs of life sciences tenants and support long-term asset value.
More from our portfolio
Seeing potential first is what sets us apart. In every market we serve, we move early, think boldly and turn possibility into long-term value.
The information appearing on RMR’s website includes statements which constitute forward looking statements. These forward looking statements are based upon RMR’s present intents, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur. Actual results may differ materially from those contained in forward looking statements. The information contained in DHC’s filings with the Securities and Exchange Commission, including under “Risk Factors" and “Warnings Concerning Forward Looking Statements” in DHC’s periodic reports and other filings, identifies important factors that could cause DHC’s actual results to differ materially from those stated in DHC’s forward looking statements. DHC’s filings with the SEC are available on the SEC’s website at www.sec.gov and are also accessible on DHC’s website at the following link: SEC Filings. You should not place undue reliance upon forward looking statements.